阿尔尼拉姆制药公司(ALNY)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ALNY 阿尔尼拉姆制药公司

已收盘 07-02 16:00:00 EDT

247.61

+4.29

+1.76%

盘后247.61

+0.000.00%

18:21 EDT

最高250.11	最低242.08	成交量157.93万
今开243.00	昨收243.32	日振幅3.30%
总市值313.21亿	流通市值311.83亿	总股本1.26亿
成交额3.90亿	换手率1.25%	流通股本1.26亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"ALNY","market":"US","secType":"STK","nameCN":"阿尔尼拉姆制药公司","latestPrice":247.61,"timestamp":1719950400000,"preClose":243.32,"halted":0,"volume":1579308,"hourTrading":{"tag":"盘后","latestPrice":247.61,"preClose":247.61,"latestTime":"18:21 EDT","volume":33371,"amount":8263310.19,"timestamp":1719958874418},"delay":0,"floatShares":125934366,"shares":126491778,"eps":-2.647864,"marketStatus":"已收盘","marketStatusCode":5,"change":4.29,"latestTime":"07-02 16:00:00 EDT","open":243,"high":250.11,"low":242.075,"amount":390467320.266,"amplitude":0.033022,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.647864,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1719993600000},"adr":0,"listingDate":1085630400000,"adjPreClose":243.32,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":243.31,"preClose":243.32,"latestTime":"09:29 EDT","volume":1334,"amount":324179.1419,"timestamp":1719926999999},"postHourTrading":{"tag":"盘后","latestPrice":247.61,"preClose":247.61,"latestTime":"18:21 EDT","volume":33371,"amount":8263310.19,"timestamp":1719958874418},"volumeRatio":0.536715,"impliedVol":0.3737,"impliedVolPercentile":0.0516},"requestUrl":"/m/hq/s/ALNY/tweets","defaultTab":"tweets","newsList":[{"id":"2446829483","title":"BUZZ-券商观点：分析师称赞 Alnylam 的心脏药物 \"明显获胜","url":"https://stock-news.laohu8.com/highlight/detail?id=2446829483","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446829483?lang=zh_cn&edition=full","pubTime":"2024-06-26 00:39","pubTimestamp":1719333580,"startTime":"0","endTime":"0","summary":"    6月25日 - ** Alnylam Pharmaceuticals   周一称，在一项涉及罕见心脏病患者的研究中，其药物vutrisiran可将死亡 ，并将心脏问题减少三分之一。** 认为该药的上市可能会带来明确的盈利途径和潜在的并购选择** TD Cowen 称数据是 \"明显的胜利\"，支持 vutrisiran \"直截了当、毫不拖泥带水 \"地获得加速批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BUZZ","ALNY","BK4588","BK4585","BK4548","BK4139"],"gpt_icon":0},{"id":"2446477698","title":"阿里拉姆制药盘中异动 股价大涨5.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2446477698","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446477698?lang=zh_cn&edition=full","pubTime":"2024-06-25 22:44","pubTimestamp":1719326656,"startTime":"0","endTime":"0","summary":"北京时间2024年06月25日22时44分，阿里拉姆制药股票出现异动，股价急速拉升5.21%。阿里拉姆制药股票所在的生物技术行业中，整体涨幅为1.80%。消息层面，截至22时44分，《Form 144 | 阿里拉姆制药董事拟出售3.25万股股份，价值约716.14万美元》资讯为影响阿里拉姆制药的重要信息。其中，关联方必须持有证券至少六个月，卖出的股数不得超过已发行股份总数的1%。关联方在任何三个月期间出售的股票数量超过5,000股时，或总市值超5万美元时须向SEC提交该表格。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062522441696816a87&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062522441696816a87&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ALNY","BK4585","BK4548","BK4139","BK4588"],"gpt_icon":0},{"id":"2446860353","title":"美国研究综述-Alimera Sciences、Comtech Telecommunications、礼来公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2446860353","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446860353?lang=zh_cn&edition=full","pubTime":"2024-06-25 15:19","pubTimestamp":1719299996,"startTime":"0","endTime":"0","summary":"    路透6月25日 - 华尔街证券分析师周二调整了对几家美国上市公司的评级和目标价，其中包括 Alimera Sciences、Comtech Telecommunications 和礼来公司。要闻             * Alimera Sciences Inc   ：Craig-Hallum将其评级从 \"买入 \"下调至 \"持有\"。* Comtech Telecommunications Corp   ：杰富瑞将其评级从 \"表现不佳 \"上调至 \"持有\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0266013472.USD","XAIR","LU0128526141.USD","LU2468319806.SGD","WOLF","BK4139","BK4520","LU0053671581.USD","BK4144","SUM","AVAV","BK4590","ZETA","ALNY","FMC","LU0456855351.SGD","RXO","LU0708995401.HKD","LU1057294990.SGD","LU0238689110.USD","LU1861220033.SGD","LU2237438978.USD","OMI","ALIM","BK4023","LU0061475181.USD","CMTL","OLLI","MLM","CTVA","LLY","EPD","POOL","BK4159","EXP","LU0471298777.SGD","LU1861215975.USD","IE00BJT1NW94.SGD","FRPT","LU0289739699.SGD","VMC","LU1852331112.SGD","IE00B1BXHZ80.USD","BK4539","BK4011","LU1150488135.SGD","EAT","LU0029874061.USD","SNCY","IONS"],"gpt_icon":0},{"id":"2446348859","title":"因肯定性心脏药物数据，Alnylam大涨35%，分析师：预计37亿美元峰值销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2446348859","media":"格隆汇","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446348859?lang=zh_cn&edition=full","pubTime":"2024-06-25 10:38","pubTimestamp":1719283120,"startTime":"0","endTime":"0","summary":"创近两年新高","market":"sg","thumbnail":"https://img3.gelonghui.com/fdfc2-077a63c5-d0dd-4ef1-ae59-08f368883916.jpg?guru_height=833&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/fdfc2-077a63c5-d0dd-4ef1-ae59-08f368883916.jpg?guru_height=833&guru_width=1280"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/810545","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK4139","BK4548","ALNY","BK4588","BK4585"],"gpt_icon":0},{"id":"2446000300","title":"BUZZ--美国股票走势-Arrowhead Pharmaceuticals、Nvidia、Alimera Sciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2446000300","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446000300?lang=zh_cn&edition=full","pubTime":"2024-06-25 01:58","pubTimestamp":1719251898,"startTime":"0","endTime":"0","summary":"        *      个股异动的 Eikon 搜索字符串：[STXBZ］        *      The Day Ahead 新闻通讯：          *      The Morning News Call时事通讯：      6月24日 - 周一，蓝筹股道指创下一个月新高，市场普遍反弹，投资者纷纷撤出与人工智能相关的股票，而市场焦点转向本周晚些时候公布的关键通胀数据，以加强对今年降息的押注。美东时间13:42，道琼斯工业平均指数  上涨0.65%，报39,405.62点。标普500指数  下跌0.01%，报5464.16点；纳斯达克综合指数  下跌0.69%，报17566.534点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1316542783.SGD","BK4528",".DJI","BUZZ","LU0109392836.USD","LU0310800965.SGD","DJX","ALIM","SQQQ","BK4529",".IXIC","PYPL","UDOW","DOG","BK4575","MAX","AFRM","BA","DDM","TQQQ","QLD","RMD","SON","MU","NQmain","SMCI","COIN","PSQ","IE00BDCRKT87.USD","QQQ","LU0642271901.SGD","QID","EOSE","MARA","MNQmain","SDOW","DXD","BK4077","ALNY","NNE","SQ","LU0289961442.SGD","NVDA","FDX","RXO","ARWR","CARR","IE00BJJMRY28.SGD","RIOT","SNV"],"gpt_icon":0},{"id":"2446007110","title":"BUZZ-Alnylam 因心脏病药物在关键研究中获得成功而跃升","url":"https://stock-news.laohu8.com/highlight/detail?id=2446007110","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446007110?lang=zh_cn&edition=full","pubTime":"2024-06-25 01:42","pubTimestamp":1719250931,"startTime":"0","endTime":"0","summary":" (更新)    6月24日 - ** Alnylam Pharmaceuticals  股价大涨40%至231.64美元，创下自2023年2月以来的最高水平 。** 如果涨势保持，市值将增加80多亿美元** 该公司称其心脏病药物vutrisiran在一项受到密切关注的后期研究中达到了  主要目标和所有次要目标** 该药物vutrisiran有助于将一种被称为ATTR-CM的罕见心脏病患者的死亡人数和心脏相关住院治疗人数减少33%。** ALNY 公司的药物通过关闭转甲状腺素蛋白的不规则生产而发挥作用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861558580.USD","NTLA","IONS","BK4139","BBIO","BK4588","BUZZ","ALNY","LU1861559042.SGD","BK4556","BK4585","BK4535","BK4548","BK4505"],"gpt_icon":0},{"id":"2445280006","title":"BUZZ--美国股票走势-布洛克、梅塔、Eos 能源","url":"https://stock-news.laohu8.com/highlight/detail?id=2445280006","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445280006?lang=zh_cn&edition=full","pubTime":"2024-06-24 23:45","pubTimestamp":1719243934,"startTime":"0","endTime":"0","summary":"        *      个股异动的 Eikon 搜索字符串：[STXBZ］        *      The Day Ahead 新闻通讯：          *      The Morning News Call时事通讯：      6月24日 - 纳斯达克指数周一下滑，受Nvidia和其他芯片股疲软拖累，同时投资者为本周一项关键的通胀数据做准备，该数据可能进一步影响对降息时机和幅度的押注。美东时间11:32，道琼斯工业平均指数  上涨0.99%，报39,536.89点。标普500指数  上涨0.27%，报5479.62点；纳斯达克综合指数  下跌0.31%，报17635.091点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RMD","IE00B19Z3B42.SGD","QLD","MU","META","BK4564","SNV","QID",".DJI","FDX","BA","MNQmain","IE0004445239.USD","BK4550","IE00B1XK9C88.USD","DJX","AFRM","RIOT","BK4516","DOG","QQQ","BK4512","SMCI","COIN","NVDA","ARWR","GB00BDT5M118.USD","PSQ","LU1571399168.USD","NQmain","MARA","BUZZ",".IXIC","BK4567","CARR","UDOW","BK4232","EOSE","SQ","LU0648001328.SGD","ALNY","TQQQ","SON","SQQQ","DDM","IE00BJTD4N35.SGD","SDOW","RXO","DXD","BK4112",".SPX"],"gpt_icon":0},{"id":"2445074984","title":"阿里拉姆制药盘中异动 大幅拉升31.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2445074984","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445074984?lang=zh_cn&edition=full","pubTime":"2024-06-24 21:31","pubTimestamp":1719235882,"startTime":"0","endTime":"0","summary":"北京时间2024年06月24日21时31分，阿里拉姆制药股票出现波动，股价大幅拉升31.83%。阿里拉姆制药股票所在的生物技术行业中，整体涨幅为0.89%。其相关个股中，Rocket Pharmaceuticals Inc C/Wts 02/09/2026 、Revelation Biosciences, Inc.、阿里拉姆制药涨幅较大，Revelation Biosciences, Inc.、Gri Bio, Inc.、Effector Therapeutics, Inc.较为活跃，换手率分别为196.80%、41.79%、26.46%，振幅较大的相关个股有Psyence Biomedical Ltd.、Unicycive Therapeutics, Inc.、Edesa Biotech, Inc.，振幅分别为9.92%、7.02%、5.15%。阿里拉姆制药公司简介：Alnylam Pharmaceuticals是RNA干扰治疗研究的领导者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406242131229f5ffff8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406242131229f5ffff8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4588","BK4139","ALNY","BK4548"],"gpt_icon":0},{"id":"2445020194","title":"BUZZ-Alnylam 因心脏病药物在后期试验中获得成功而跃升","url":"https://stock-news.laohu8.com/highlight/detail?id=2445020194","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445020194?lang=zh_cn&edition=full","pubTime":"2024-06-24 19:33","pubTimestamp":1719228808,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    6月24日 - ** Alnylam Pharmaceuticals  股价盘前大涨31%至217.02美元** 该公司称其心脏病药物vutrisiran在 一项 后期研究中达到了 (link)，减少了死亡和复发性心血管事件的主要目标。** 该公司称，该研究的所有次要目标也已实现** ALNY计划今年晚些时候向美国申请批准该药物** 截至收盘，ALNY股价累计下跌13.4%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY","BK4139","BUZZ","BK4548","BK4588","BK4585"],"gpt_icon":0},{"id":"2445022051","title":"Alnylam 的心脏病药物在后期研究中达到主要目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2445022051","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445022051?lang=zh_cn&edition=full","pubTime":"2024-06-24 19:05","pubTimestamp":1719227148,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透6月24日 - Alnylam Pharmaceuticals   周一表示，其药物vutrisiran在一项晚期研究中达到了主要目标，该研究测试该药物作为一种心脏病的治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY","BK4139","BK4548","BK4585","BK4588"],"gpt_icon":0},{"id":"2445763680","title":"阿里拉姆制药盘中异动 早盘股价大涨5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2445763680","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445763680?lang=zh_cn&edition=full","pubTime":"2024-06-21 21:50","pubTimestamp":1718977831,"startTime":"0","endTime":"0","summary":"北京时间2024年06月21日21时50分，阿里拉姆制药股票出现波动，股价大幅拉升5.16%。截至发稿，该股报165.52美元/股，成交量9.4181万股，换手率0.07%，振幅4.31%。阿里拉姆制药股票所在的生物技术行业中，整体跌幅为0.31%。阿里拉姆制药公司简介：Alnylam Pharmaceuticals是RNA干扰治疗研究的领导者。RNAi是细胞内一种自然发生的生物通路，用于序列特异性沉默和调控基因表达。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240621215032941f0220&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240621215032941f0220&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4548","BK4139","ALNY","BK4585","BK4588"],"gpt_icon":0},{"id":"2434286979","title":"阿里拉姆制药2024财年第一财季实现净利润-65.94百万美元，同比增加62.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2434286979","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434286979?lang=zh_cn&edition=full","pubTime":"2024-05-11 00:22","pubTimestamp":1715358124,"startTime":"0","endTime":"0","summary":"3月31日，阿里拉姆制药公布财报，公告显示公司2024财年第一财季净利润为-65.94百万美元，同比增加62.10%；其中营业收入为4.94亿美元，同比增加54.86%，每股基本收益为-0.52美元。从资产负债表来看，阿里拉姆制药总负债40.44亿美元，其中短期债务87.85百万美元，资产负债比为0.95，流动比率为3.18。机构评级：截至2024年3月31日，当前有24家机构对阿里拉姆制药目标价做出预测，其中目标均价为218.58美元，其中最低目标价为138.00美元，最高目标价为400.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405110022098751715f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405110022098751715f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ALNY"],"gpt_icon":0},{"id":"2432343819","title":"Needham：重申Alnylam Pharmaceuticals(ALNY.US)评级，由买入调整至买入评级, 目标价200.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2432343819","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2432343819?lang=zh_cn&edition=full","pubTime":"2024-05-03 02:45","pubTimestamp":1714675534,"startTime":"0","endTime":"0","summary":"Needham：重申Alnylam Pharmaceuticals(ALNY.US)评级，由买入调整至买入评级, 目标价200.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405030245388b6df5af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405030245388b6df5af&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ALNY"],"gpt_icon":0},{"id":"2432091786","title":"Alnylam Pharmaceuticals Inc 报告截至三月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2432091786","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2432091786?lang=zh_cn&edition=full","pubTime":"2024-05-02 21:33","pubTimestamp":1714656792,"startTime":"0","endTime":"0","summary":"   * Alnylam Pharmaceuticals Inc    公布，在截至 3 月份的季度调整后每股亏损 52 美分，高于去年同期的每股收益 1.40 美元。25 位分析师对该季度的平均预期是每股亏损 1.18 美元。华尔街预期为每股亏损 1.56 美元至-27 美分。* Alnylam Pharmaceuticals Inc公布的本季度每股收益为亏损52美分。* 该公司报告的季度亏损额为 6594 万美元。* Alnylam Pharmaceuticals Inc 本季度股价上涨了 0.3%，今年迄今为止亏损了 21.7%。* 华尔街对 Alnylam Pharmaceuticals Inc 的 12 个月目标价中位数为 221.00 美元。(如对本报告中的数据有任何疑问，请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY","BK4588","BK4548","BK4139","BK4585"],"gpt_icon":0},{"id":"2432263374","title":"阿里拉姆制药盘中异动 下午盘股价大涨5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2432263374","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2432263374?lang=zh_cn&edition=full","pubTime":"2024-05-02 02:58","pubTimestamp":1714589900,"startTime":"0","endTime":"0","summary":"北京时间2024年05月02日02时58分，阿里拉姆制药股票出现异动，股价快速上涨5.06%。截至发稿，该股报151.23美元/股，成交量26.9002万股，换手率0.21%，振幅4.84%。阿里拉姆制药股票所在的生物技术行业中，整体涨幅为2.21%。阿里拉姆制药公司简介：Alnylam Pharmaceuticals是RNA干扰治疗研究的领导者。RNAi是细胞内一种自然发生的生物通路，用于序列特异性沉默和调控基因表达。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405020258207a57df98&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405020258207a57df98&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4548","BK4139","ALNY","BK4585","BK4588"],"gpt_icon":0},{"id":"2432771513","title":"Alnylam Pharmaceuticals Inc    预计每股亏损 1.18 美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2432771513","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2432771513?lang=zh_cn&edition=full","pubTime":"2024-05-01 00:23","pubTimestamp":1714494226,"startTime":"0","endTime":"0","summary":"   * Alnylam Pharmaceuticals Inc     将于5月2日公布截至2024年3月31日的财报，预计该公司的季度收入将有所增长。* LSEG 分析师对 Alnylam Pharmaceuticals Inc 的平均预期为每股亏损 1.18 美元。* 华尔街对 Alnylam Pharmaceuticals Inc 的 12 个月目标价中位数为 221.00 美元，高于其最新收盘价 147.36 美元。4月30日 - 上一季度业绩。除非另有说明，所有数字均以美元为单位。(如对本报告中的数据有任何疑问，请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"gpt_icon":0},{"id":"2428523597","title":"健康巡诊：尿检发现令人担忧的前列腺癌，避免不必要的活组织检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2428523597","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2428523597?lang=zh_cn&edition=full","pubTime":"2024-04-19 05:40","pubTimestamp":1713476405,"startTime":"0","endTime":"0","summary":"另一个是一种检测前列腺癌的尿检方法，可以减少活检的需要。尿检可发现令人担忧的前列腺癌研究人员周四在《美国医学会肿瘤学杂志》上报告说，一种新型尿液检验能比标准血液检验更准确地检测出需要治疗的前列腺癌，并能减少不必要的活组织检查。由于前列腺癌在黑人男性中更为常见，研究人员正在更多种族的人群中开展进一步的试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","PSA","ALNY","BK4548","BK4084","BK4588","BK4139","BK4585","BK4217"],"gpt_icon":0},{"id":"2417415513","title":"罗氏和 Alnylam 称降压药在中期试验中获得成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2417415513","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2417415513?lang=zh_cn&edition=full","pubTime":"2024-03-05 21:27","pubTimestamp":1709645234,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透社法兰克福3月5日 - 罗氏公司  和合作伙伴Alnylam公司  周二称，在一项二期试验中，他们研制的治疗高血压的试验性药物在与标准疗法联合使用时显示出了效果。罗氏公司周二在一份声明中说，KARDIA-2二期试验将于4月6日在亚特兰大举行的美国心脏病学会科学年会上公布全部结果。去年 7 月，罗氏同意开发 Alnylam 的 zilebesiran 并将其商业化，用于治疗高血压这一全球心血管疾病的主要病因。罗氏当时向 Alnylam 支付了 3.1 亿美元的预付款，并支付了里程碑付款，使这笔交易的潜在价值高达 28 亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","ALNY","BK4139"],"gpt_icon":0},{"id":"2413782240","title":"阿里拉姆制药盘中异动 下午盘急速拉升5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2413782240","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2413782240?lang=zh_cn&edition=full","pubTime":"2024-02-23 03:00","pubTimestamp":1708628433,"startTime":"0","endTime":"0","summary":"北京时间2024年02月23日03时00分，阿里拉姆制药股票出现波动，股价大幅上涨5.05%。截至发稿，该股报162.55美元/股，成交量61.5857万股，换手率0.49%，振幅5.29%。阿里拉姆制药股票所在的生物技术行业中，整体涨幅为2.26%。阿里拉姆制药公司简介：Alnylam Pharmaceuticals是RNA干扰治疗研究的领导者。RNAi是细胞内一种自然发生的生物通路，用于序列特异性沉默和调控基因表达。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022303003387e724fe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022303003387e724fe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4548","BK4139","ALNY"],"gpt_icon":0},{"id":"2412997488","title":"阿里拉姆制药2023财年实现净利润-4.40亿美元，同比增加61.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2412997488","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2412997488?lang=zh_cn&edition=full","pubTime":"2024-02-19 00:20","pubTimestamp":1708273216,"startTime":"0","endTime":"0","summary":"12月31日，阿里拉姆制药公布财报，公告显示公司2023财年净利润为-4.40亿美元，同比增加61.10%；其中营业收入为18.28亿美元，同比增加76.28%，每股基本收益为-3.52美元。从资产负债表来看，阿里拉姆制药总负债40.51亿美元，其中短期债务96.50百万美元，资产负债比为0.95，流动比率为3.09。机构评级：截至2023年12月31日，当前有23家机构对阿里拉姆制药目标价做出预测，其中目标均价为219.35美元，其中最低目标价为136.00美元，最高目标价为395.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240219002028879e45cd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240219002028879e45cd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ALNY"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alnylam.com","stockEarnings":[{"period":"1week","weight":0.0916},{"period":"1month","weight":0.6393},{"period":"3month","weight":0.611},{"period":"6month","weight":0.2763},{"period":"1year","weight":0.281},{"period":"ytd","weight":0.2712}],"compareEarnings":[{"period":"1week","weight":0.0048},{"period":"1month","weight":0.0341},{"period":"3month","weight":0.0511},{"period":"6month","weight":0.1633},{"period":"1year","weight":0.2302},{"period":"ytd","weight":0.1473}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Alnylam Pharmaceuticals, Inc.是一家特拉华州公司，成立于2003年5月。该公司是一家研发基于RNA或RNAi干涉为新型治疗手段的生物制药公司。RNAi是一种在生物体内细胞中自然产生的选择性沉默及调控表达的特定基因。由于许多疾病是因为特定基因的不适当活动引起的，通过RNAi对于基因的选择性沉默能力可以为治疗许多人类疾病提供一种新的途径。公司认为，通过RNAi原理工作的药物有潜力成为的一种新的药物分类，诸如小分子药物、蛋白质药物以及抗体药物等。通过已经建立RNAi的知识产权以及专业技术，公司正在开发一套生物化学方法以帮助公司建立一个系统，通过该系统可以研发改进RNAi对于各种疾病的治疗方案。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.031314},{"month":2,"riseRate":0.5,"avgChangeRate":0.008316},{"month":3,"riseRate":0.45,"avgChangeRate":-0.018527},{"month":4,"riseRate":0.4,"avgChangeRate":-0.019432},{"month":5,"riseRate":0.6,"avgChangeRate":0.035453},{"month":6,"riseRate":0.619048,"avgChangeRate":0.064199},{"month":7,"riseRate":0.714286,"avgChangeRate":0.103505},{"month":8,"riseRate":0.55,"avgChangeRate":0.028475},{"month":9,"riseRate":0.5,"avgChangeRate":0.034438},{"month":10,"riseRate":0.4,"avgChangeRate":-0.044685},{"month":11,"riseRate":0.8,"avgChangeRate":0.089497},{"month":12,"riseRate":0.5,"avgChangeRate":0.016329}],"exchange":"NASDAQ","name":"阿尔尼拉姆制药公司","nameEN":"Alnylam Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"阿尔尼拉姆制药公司(ALNY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供阿尔尼拉姆制药公司(ALNY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"阿尔尼拉姆制药公司,ALNY,阿尔尼拉姆制药公司股票,阿尔尼拉姆制药公司股票老虎,阿尔尼拉姆制药公司股票老虎国际,阿尔尼拉姆制药公司行情,阿尔尼拉姆制药公司股票行情,阿尔尼拉姆制药公司股价,阿尔尼拉姆制药公司股市,阿尔尼拉姆制药公司股票价格,阿尔尼拉姆制药公司股票交易,阿尔尼拉姆制药公司股票购买,阿尔尼拉姆制药公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"阿尔尼拉姆制药公司(ALNY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供阿尔尼拉姆制药公司(ALNY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}